Journal of Environmental Science International (한국환경과학회지)

The Korean Environmental Sciences Society (한국환경과학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of Momordica charantia on Glucagon Secretion in High-fat diet(HFD)/Streptozotocin(STZ)-induced Diabetic Rat

고지방식이(HFD)/stereptozotocin(STZ) 유도 당뇨모델에서 여주가 글루카곤 분비에 미치는 영향

  • 김성은 (콜마비앤에이치(주) 식품과학연구소) ;
  • 김상백 ((주)한국콜마 피부천연물연구소) ;
  • 김슬기 (콜마비앤에이치(주) 식품과학연구소) ;
  • 김현규 (콜마비앤에이치(주) 식품과학연구소) ;
  • 박병준 ((주)한국콜마 피부천연물연구소) ;
  • 이학성 (콜마비앤에이치(주) 식품과학연구소)
  • Received : 2020.07.08
  • Accepted : 2020.08.14
  • Published : 2020.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

In present study, we investigated the antidiabetic effect of Momordica charantia(as well known "bitter melon"). This study was conducted to determine antidiabetic mechanism of Bitter Melon Extract (BME). We measured blood glucose, insulin, glucagon level in a Sprague-Dawley rat model of high-fat diet/streptozotocin(HFD/STZ)-induced diabetes. Five experimental groups were used: normal, HFD/STZ, BME 62.5 mg/kg HFD/STZ, BME 125 mg/kg HFD/STZ and BME 250 mg/kg HFD/STZ. BME was orally administered to the rats every other day for 9 weeks. Results showed that fasting blood glucose levels were significantly lower in the BME 125 mg/kg(150.17 ± 20.22 mg/dL) and 250 mg/kg(124.17 ± 22.17 mg/dL) groups than in the vehicle group(188.83 ± 26.63 mg/dL)(p<0.05). In addition, glucagon levels were lower in the three BME treatment groups than in the vehicle group(p<0.05). Oral glucose tolerance tests revealed that the BME 250 mg/kg group had significantly(p<0.05) reduced 120-minute blood glucose levels and areas under the curve. Our results suggest that BME induces antidiabetic effects via the reduction of glucagon and blood glucose levels.

Keywords

References

  1. Adeghate, E., Schattner, P., Dunn, E., 2006, An Update on the etiology and epidemiology of diabetes mellitus., Ann. N. Y. Acad. Sci., 1084, 1-29. https://doi.org/10.1196/annals.1372.029
  2. Ahmed, I., Adeghate, E., Sharma, A. K., Pallot, D. J., Singh, J., 1998, Effects of Momordica charantia fruit juice on islet morphology in the pancreas of the streptozotocin-diabetic rat., Diabetes. Res. Clin. Pract., 40, 145-151. https://doi.org/10.1016/S0168-8227(98)00022-9
  3. Beloin, N., Gbeassor, M., Akpagana, K., Hudson, J., de Soussa, K., Koumaglo, K., Arnason, J. T.. 2005, Ethnomedicinal uses of Momordica charantia (Cucurbitaceae) in Togo and relation to its phytochemistry and biological activity., J. Ethnopharmacol., 96, 49-55. https://doi.org/10.1016/j.jep.2004.08.009
  4. Bhat, G. A., Khan, H. A., Alhomida, A. S., Sharma, P., Singh, R., Paray, B. A., 2018, GLP-1 secretion in healthy and diabetic Wistar rats in response to aqueous extract of Momordica charantia., BMC Complement. Altern. Med., 18, 162. https://doi.org/10.1186/s12906-018-2227-4
  5. Consoli, A., 1992, Role of Liver in Pathophysiology of NIDDM., Diabetes. Care., 15, 430-441. https://doi.org/10.2337/diacare.15.3.430
  6. Elekofehinti, O. O., Ariyo, E. O., Akinijiyan, M. O., Olayeriju, O. S., Lawal, A. O., Adanlawo, I. G., Rocha, J. B. T., 2018, Potential use of bitter melon(Momordica charantia) derived compounds as antidiabetics: In silico and in vivo studies. Pathophysiology., 25, 327-333. https://doi.org/10.1016/j.pathophys.2018.05.003
  7. Grover, J. K., Rathi, S. S., Vats V., 2002, Amelioration of experimental diabetic neuropathy and gastropathy in rats following oral administration of plant(Eugenia jambolana, Mucuna pruriens and Tinospora cordifolia) extracts. Indian. J. Exp. Biol., 40, 273-276.
  8. Grover, J. K., Vats, V., Rathi, S. S., Dawar, R., 2001, Traditional Indian anti-diabetic plants attenuate progression of renal damage in streptozotocin induced diabetic mice. J. Ethnopharmacol., 76, 233-238. https://doi.org/10.1016/S0378-8741(01)00246-X
  9. Grover, J. K., Yadav, S. P., 2004, Pharmacological actions and potential uses of Momordica charantia: a review., J. Ethnopharmacol., 93, 123-132. https://doi.org/10.1016/j.jep.2004.03.035
  10. Jiang, G., Zhang, B. B., 2003, Glucagon and regulation of glucose metabolism., Am. J. Physiol. Endocrinol. Metab., 284, E671-E678. https://doi.org/10.1152/ajpendo.00492.2002
  11. Kim, J. W., Lee, Y. S., Seol, D. J., Cho, I. J., Ku, S. K., Choi, J. S., Lee, H. J.. 2018, Anti-obesity and fatty liver -preventing activities of Lonicera caerulea in high-fat diet-fed mice. Int. J. Mol. Med., 42, 3047-64.
  12. Kim, Y. J., Kim, H. K., Lee, H. S., 2018, Hypoglycemic effect of standardized Chrysanthemum zawadskii ethanol extract in high-fat diet/streptozotocin-induced diabetic mice and rats., Food. Sci. Biotechnol., 27, 1771-1779. https://doi.org/10.1007/s10068-018-0399-9
  13. Kyoung, S. P., 2018, DIABETES FACT SHEET IN KOREA. Korea Diabetes Association, Seoul, Korea.
  14. Lee, M. Y., Kim, M. K., Park, J. S., Lee, S. B., You, J. H., Ahn, C. W., Kim, K. R., Kang, S. N., 2019, Higher Glucagon-to-Insulin Ration Is Associated With Elevated Glycated Hemoglobin Levels in Type 2 Diabetes Patients., Korean. J. Intern. Med., 34, 1068-1077. https://doi.org/10.3904/kjim.2016.233
  15. Raman, A., Lau, C., 1996, Anti-diabetic properties phytochemistry of Momordica charantia L. (Cucurbitaceae)., Phytomedicine., 2, 349-362. https://doi.org/10.1016/S0944-7113(96)80080-8
  16. Rathi, S. S., Grover, J. K., Vikrant, V., Biswas, N. R.. 2002, Prevention of experimental diabetic cataract by Indian Ayurvedic plants extracts., Phytother. Res., 16, 774-777. https://doi.org/10.1002/ptr.1064
  17. Shih, C. C., Shlau, M. T., Lin, C. H., Wu, J. B., 2014, Momordica charantia Ameliorates Insulin Resistance and Dyslipidemia with Altered Hepatic Glucose Prodcution and Fatty Acid Synthesis and AMPK Phosphorylation in High-fat-fed Mice., Phytother. Res., 28, 363-371. https://doi.org/10.1002/ptr.5003
  18. Son, H. S., 2008, Early Diagnosis of Diabetes Mellitus. J. Korean. Med. Assoc., 51, 813-817. https://doi.org/10.5124/jkma.2008.51.9.813
  19. Stratton, I. M., Adler, A. I., Neil, H. A. W., Matthews, D. R., Manley, S. E., Cull, C. A., Hadden, D., Turner, R. C., Holman, R. R., 2000, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ., 321, 405-412. https://doi.org/10.1136/bmj.321.7258.405
  20. Vikrant, V., Grover, J. K., Tandon, N., Rathi, S. S., Gupta, N., 2001, Treatment with extracts of Momordica charantia and Eugenia jambolana prevents hyperglycemia and hyperinsulinemia in fructose fed rats. J. Ethnopharmacol., 76, 139-143. https://doi.org/10.1016/S0378-8741(01)00218-5
  21. Wang, L., Waltenberger, B., Pferschy-Wenzig, E. M., Blunder, M., Liu, X., Malanier, C., Blazevic, T., Schwaiger, S., Rollinger, J. M., Heiss, E. H., Schuster, D., Kopp, B., Bauer, R., Stuppner, H., Dirsch, V. M., Atanasov, A. G., 2014, Natural product agonists of peroxisome proliferator-activated receptor gamma ($PPAR{\gamma}$): a review. Biochem. Pharmacol., 92, 73-89. https://doi.org/10.1016/j.bcp.2014.07.018